Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2019 08:30 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck

BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
November 30, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference

- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the...
November 13, 2018 11:50 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference

- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...
November 12, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update

BOTHELL, WA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
October 08, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus

- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...
September 20, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Completes Patient Enrollment in Phase 2a Study Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C

ATLANTA, GA and BOTHELL, WA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
August 09, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update

– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
June 28, 2018 07:35 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV

- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
June 25, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Inclusion in Russell Microcap® Index

ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
June 04, 2018 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony

ATLANTA, GA and BOTHELL, WA, June 04, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...